OT: Stock trading | Page 67 | The Boneyard

OT: Stock trading

Kemba'sYogurt said:
What do you think about holding Tesla for 10-15 years? Thinking about buying in soon and doing this.
Expand ...
For that long of a time horizon I think it’s a great move. Tesla stock is very volatile but for its vision, execution and total addressable market, still great to have. Although I have some now, 3 of my 5 biggest mistakes this year were the times I sold some Tesla. I’ve regretted it every single time.
 
I Bleed Blue said:
I’m salty about not jumping into ARKK earlier this summer. I too waited for a significant dip that never happened.
Expand ...

I just hope I don't hold too long. There is no way this keeps going.

But I'm glad I didn't take profits when it was up "merely" 30% in two months.
 
Da_Aisijimo_Gou said:
Yes, implied opportunity for others looking to initially get in or to average down. Holding more than enough BABA at break even <188, not interested in adding more yet appreciated the resulting opportunity to add some discounted JD pre-mkt and TCEHY.

Winnie’s (Xi) containing BABA’s lending to unworthy borrowers, imposing reasonable lending regs, and breaking BABA’s monopolistic seller rules which effectively require selling companies to only use BABA vs other platforms, e.g., JD, PDD, etc. No negative impact on BABA’s massive cloud opportunity, ongoing revenues from Alipay and other services, and eventually good for their Ant IPO.
Expand ...

I bought BABA and sold it. Just front trust it. I’m also going to avoid Chinese companies at this point.
 
Tenspro2002 said:
My innovation fund (ARKK) is up 60% since August. Everything else I sold too early expecting a dip.
Expand ...
God bless Catherine Wood and her ARK Invest family.

ARK Invest funds have been the easiest money this year.

Four of the 5 ARK etfs have more than tripled this year with the 5th up more than 2X. Take a look:

ARKG last @ $103.10
52 week range $24.00 to 108.14

ARKF last @ $50.29
52 week range $16.94 to 52.21

ARKK last @ $133.03
52 week range $33.00 to 137.08

ARKW last @ $151.38
52 week range $40.49 to 155.00

PRNT (3D printing) last @ $32.16
52 week range $13.80 to 33.24




 
Bobol said:
God bless Catherine Wood and her ARK Invest family.

ARK Invest funds have been the easiest money this year.

Four of the 5 ARK etfs have more than tripled this year with the 5th up more than 2X. Take a look:

ARKG last @ $103.10
52 week range $24.00 to 108.14

ARKF last @ $50.29
52 week range $16.94 to 52.21

ARKK last @ $133.03
52 week range $33.00 to 137.08

ARKW last @ $151.38
52 week range $40.49 to 155.00

PRNT (3D printing) last @ $32.16
52 week range $13.80 to 33.24




Expand ...
I have her mutual fund - ADNPX. I got in this past November 2nd, its up at amazing 40% since then.
 
Scud49 said:
I have her mutual fund - ADNPX. I got in this past November 2nd, its up at amazing 40% since then.
Expand ...
With similar objectives, holdings, risk, volatility, and close returns, why buy the high front-end loaded ADNPX with markedly-higher annual fees and a shorter track record (2017) vs ARKK (est 2014) with no front-end and just 45% of ADNPX's annual fees?
 
Bobol said:
God bless Catherine Wood and her ARK Invest family.

ARK Invest funds have been the easiest money this year.

Four of the 5 ARK etfs have more than tripled this year with the 5th up more than 2X. Take a look:

ARKG last @ $103.10
52 week range $24.00 to 108.14

ARKF last @ $50.29
52 week range $16.94 to 52.21

ARKK last @ $133.03
52 week range $33.00 to 137.08

ARKW last @ $151.38
52 week range $40.49 to 155.00

PRNT (3D printing) last @ $32.16
52 week range $13.80 to 33.24

ARKK is the one I’ve been looking to add. Have considered taking great gains I’ve had on my own and turn it over to Cathie and Co.
Expand ...
 

Good reasons obviously exist to dislike Central govt party boy actions, e.g., timed BABA anti-monopoly news release before HK's brief Christmas Eve opening, and some prominent mainland accounting shysters, e.g., Luckin. However, ignoring the mainland's evolution and its' massive spike in global economy influence is challenging since first visiting (2006) and moving to the mainland (2008) for work. Somehow, Enron's and Luckin's shenanighans also didn't prevent dipping in EOG in Oct nor LKNCY in Sep.

Weekly, the mainland mints a few new USD billionaires (many female). Anyone visiting the first time and typically returnees after being away just a year are blown away by the evolution. If not mainland companies, investing 5% min of investable assets in non-mainland companies evolving with the developments may make sense. Meanwhile, not liking certain govts' actions likely won't prevent considering LU dips (wealth mgmt carve out of globally well respected Ping An) nor selectively buying/holding shares of US companies milking ongoing Fed actions.
 
Last edited:
A quick question to my fello Boneyard Stock posters ...... what services (subscription or non subscription) do you utilize for guidance in the stock market ?

I subscribe to the WSJ, Barrons, and Motley Fools Advisors. I don’t read the WSJ as much as I should and when I do then I read the WSJ mostly for news content.

I do us Barrons and Mot Fools for stock guidance and find both helpful and worth the cost. Motley Fool has given me some good selections. If you have not yet checked out the free Motley Fool and Ark Invest podcasts then you should do so.

I am considering subscribing to Investors Business Daily. Does anyone have any thoughts about IBD ?

Are there any other resources you find helpful ?

thanks
 
Bobol said:
A quick question to my fello Boneyard Stock posters ...... what services (subscription or non subscription) do you utilize for guidance in the stock market ?

I subscribe to the WSJ, Barrons, and Motley Fools Advisors. I don’t read the WSJ as much as I should and when I do then I read the WSJ mostly for news content.

I do us Barrons and Mot Fools for stock guidance and find both helpful and worth the cost. Motley Fool has given me some good selections. If you have not yet checked out the free Motley Fool and Ark Invest podcasts then you should do so.

I am considering subscribing to Investors Business Daily. Does anyone have any thoughts about IBD ?

Are there any other resources you find helpful ?

thanks
Expand ...
IBD is the primary one I use, along with CNBC Pro and stock charts.com. If I cut down to only one, it will be IBD for sure. Money well spent in my opinion.
 
I have never really read much of the services that speak to what to buy or sell. They never made sense to me for two primary reasons. First, if they truly could pick winners and losers they wouldn’t share that information. They would access capital and trade on whatever proprietary process they believe they have for their own account. Second, many of them heavily emphasize timing, which I simply don’t believe can be done.

For investing based on long term fundamentals there is just so much information available now. I even think the stock analyst reports are somewhat worthwhile now that Wall Street cleaned up its act on in what used to be a complete farce. I’ve read the WSJ for years, but mostly for general business and economic news. One of the few newspapers where I can readily determine if I’m reading the news or an editorial.
 
People with Pharma/Biotech clinical trial experience/background/knowledge regarding FDA trials:

For eIND applications (Emergency Investigational New Drug) of prospective drugs, how typical is it for the FDA to provide guidance on an open-label extension for a prospective drug's Phase 3 trial and criteria for eINDs for doctors or hospitals treating patients meeting trial criteria? For example, small biotech Cytodyn's Leronlimab (potential brand Vyrologix):

 
Da_Aisijimo_Gou said:
People with Pharma/Biotech clinical trial experience/background/knowledge regarding FDA trials:

For eIND applications (Emergency Investigational New Drug) of prospective drugs, how typical is it for the FDA to provide guidance on an open-label extension for a prospective drug's Phase 3 trial and criteria for eINDs for doctors or hospitals treating patients meeting trial criteria? For example, small biotech Cytodyn's Leronlimab (potential brand Vyrologix):

Expand ...


CYDY is a buy, great swing trade opportunity.
 
Jaker said:
CYDY is a buy, great swing trade opportunity.
Expand ...
For swinging day traders at Monday's open and potentially for the day, yet cognizant of the real possibility shorters continue slamming CYDY back down. Hence, the question seeking more general sector information from people with actual direct pharma/ biotech/ FDA knowledge possibly more relevant for investors vs day traders.
 
Despite announcing an expanded buy back, weekend Beijing announcements contribute to Alibaba sliding >5% in HK and Alibaba Health IT down >10%.
 
Da_Aisijimo_Gou said:
For swinging day traders at Monday's open and potentially for the day, yet cognizant of the real possibility shorters continue slamming CYDY back down. Hence, the question seeking more general sector information from people with actual direct pharma/ biotech/ FDA knowledge possibly more relevant for investors vs day traders.
Expand ...


Welp, thanks for asking the question, I am curious myself now. The stock was not on my radar until you brought it up, I got in and out today 3 times for some nice wins.
 
You must log in or register to reply here.

Online statistics

Members online
237
Guests online
1,615
Total visitors
1,852
Totals may include hidden visitors.

Share This Page

Forum statistics

Threads
164,007
Messages
4,378,364
Members
10,170
Latest member
ctfb19382


.
..
Top Bottom